WO2015119998A1 - 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof - Google Patents
6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof Download PDFInfo
- Publication number
- WO2015119998A1 WO2015119998A1 PCT/US2015/014380 US2015014380W WO2015119998A1 WO 2015119998 A1 WO2015119998 A1 WO 2015119998A1 US 2015014380 W US2015014380 W US 2015014380W WO 2015119998 A1 WO2015119998 A1 WO 2015119998A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxy
- pyridin
- trifluoromethyl
- alkyl
- quinolin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Quinoline Compounds (AREA)
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016550611A JP6532474B2 (ja) | 2014-02-06 | 2015-02-04 | 6−ヘテロアリールオキシ−および6−アリールオキシ−キノリン−2−カルボキシアミドならびにその使用 |
CA2938719A CA2938719A1 (en) | 2014-02-06 | 2015-02-04 | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
CN201580017702.3A CN106458985B (zh) | 2014-02-06 | 2015-02-04 | 6-杂芳氧基-和6-芳氧基-喹啉-2-甲酰胺及其用途 |
BR112016017996A BR112016017996A2 (pt) | 2014-02-06 | 2015-02-04 | 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso |
KR1020167024669A KR20160118345A (ko) | 2014-02-06 | 2015-02-04 | 6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도 |
AU2015214366A AU2015214366B2 (en) | 2014-02-06 | 2015-02-04 | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
MX2016010056A MX2016010056A (es) | 2014-02-06 | 2015-02-04 | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. |
RU2016135637A RU2016135637A (ru) | 2014-02-06 | 2015-02-04 | 6-гетероарилокси- и 6-арилоксихинолин-2-карбоксамиды и их применение |
SG11201606367YA SG11201606367YA (en) | 2014-02-06 | 2015-02-04 | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
EP15705447.9A EP3102569A1 (en) | 2014-02-06 | 2015-02-04 | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
IL247014A IL247014A0 (en) | 2014-02-06 | 2016-07-28 | 6-heteroaryloxy and 6-aryloxy-quinoline-2-carboxamides and their use |
HK17105028.6A HK1231471A1 (zh) | 2014-02-06 | 2017-05-18 | -雜芳氧基-和 芳氧基-喹啉- -甲酰胺及其用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461936397P | 2014-02-06 | 2014-02-06 | |
US61/936,397 | 2014-02-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015119998A1 true WO2015119998A1 (en) | 2015-08-13 |
Family
ID=52484589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/014380 WO2015119998A1 (en) | 2014-02-06 | 2015-02-04 | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
Country Status (14)
Country | Link |
---|---|
US (3) | US9452986B2 (pt-PT) |
EP (1) | EP3102569A1 (pt-PT) |
JP (1) | JP6532474B2 (pt-PT) |
KR (1) | KR20160118345A (pt-PT) |
CN (1) | CN106458985B (pt-PT) |
AU (1) | AU2015214366B2 (pt-PT) |
BR (1) | BR112016017996A2 (pt-PT) |
CA (1) | CA2938719A1 (pt-PT) |
HK (1) | HK1231471A1 (pt-PT) |
IL (1) | IL247014A0 (pt-PT) |
MX (1) | MX2016010056A (pt-PT) |
RU (1) | RU2016135637A (pt-PT) |
SG (1) | SG11201606367YA (pt-PT) |
WO (1) | WO2015119998A1 (pt-PT) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017518348A (ja) * | 2014-06-20 | 2017-07-06 | オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited | Irak4阻害剤としての置換インダゾール化合物 |
US10441586B2 (en) | 2015-10-07 | 2019-10-15 | Arizona Board Of Regents On Behalf Of The University Of Arizona | CRMP2 SUMOylation inhibitors and uses thereof |
WO2020054657A1 (ja) | 2018-09-10 | 2020-03-19 | 科研製薬株式会社 | 新規ヘテロ芳香族アミド誘導体及びそれを含有する医薬 |
US10758518B2 (en) | 2017-10-31 | 2020-09-01 | Curis, Inc. | Compounds and compositions for treating hematological disorders |
US10995100B2 (en) | 2014-01-13 | 2021-05-04 | Aurigene Discovery Technologies Limited | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors |
US11419875B2 (en) | 2017-03-31 | 2022-08-23 | Aurigene Discovery Technologies Limited | Compounds and compositions for treating hematological disorders |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途 |
TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
MX2016010056A (es) * | 2014-02-06 | 2016-11-15 | Abbvie Inc | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. |
US9611262B2 (en) * | 2014-09-11 | 2017-04-04 | Janssen Pharmaceutica Nv | Substituted 2-azabicycles and their use as orexin receptor modulators |
ES2829636T3 (es) * | 2015-10-09 | 2021-06-01 | Abbvie Overseas Sarl | Pirazolo[3,4-b]piridin-6-carboxamidas N-sulfoniladas y método de uso |
CN110337436A (zh) | 2016-12-22 | 2019-10-15 | 拜耳作物科学股份公司 | 取代的1,2,4-噻二唑基吡咯酮和1,2,4-噻二唑基乙内酰脲及其盐及其作为除草剂的用途 |
MX2019015895A (es) * | 2017-06-30 | 2020-02-07 | Bayer Animal Health Gmbh | Nuevos derivados de azaquinolina. |
BR112021008741A2 (pt) | 2018-11-09 | 2021-08-10 | Vivace Therapeutics, Inc. | compostos bicíclicos |
SG11202107080VA (en) * | 2019-01-11 | 2021-07-29 | Naegis Pharmaceuticals Inc | Leukotriene synthesis inhibitors |
CN114072207B (zh) * | 2019-04-16 | 2024-03-29 | 维瓦斯治疗公司 | 双环化合物 |
WO2023138599A1 (zh) * | 2022-01-18 | 2023-07-27 | 成都康弘药业集团股份有限公司 | 芳香并环类Nav1.8抑制剂及其用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005014558A1 (en) * | 2003-08-05 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Condensed pyramidine compounds as inhibitors of voltage-gated ion channels |
WO2006124744A1 (en) * | 2005-05-16 | 2006-11-23 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of ion channels |
WO2007003419A1 (en) * | 2005-07-04 | 2007-01-11 | Karo Bio Ab | Heterocyclic compounds as agonists for the thyroid receptor |
WO2007127183A1 (en) | 2006-04-26 | 2007-11-08 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
WO2010137351A1 (en) * | 2009-05-29 | 2010-12-02 | Raqualia Pharma Inc. | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers |
WO2014120815A1 (en) * | 2013-01-31 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Quinoline and quinazoline amides as modulators of sodium channels |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2391338C2 (ru) * | 2004-10-19 | 2010-06-10 | Ф.Хоффманн-Ля Рош Аг | Производные хинолина |
CN101253159B (zh) * | 2005-09-01 | 2011-12-07 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物 |
BRPI0719210A2 (pt) * | 2006-10-12 | 2015-05-05 | Xenon Pharmaceuticals Inc | Uso de compostos espiro-oxindol como agentes terapêuticos |
SA08290245B1 (ar) * | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
US9051296B2 (en) * | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
UY33372A (es) * | 2010-05-10 | 2011-12-30 | Gilead Sciences Inc | ?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?. |
CN106478497B (zh) * | 2010-10-18 | 2020-05-08 | 拉夸里亚创药株式会社 | 作为ttx-s阻滞剂的芳胺衍生物 |
MX2016010056A (es) * | 2014-02-06 | 2016-11-15 | Abbvie Inc | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. |
-
2015
- 2015-02-04 MX MX2016010056A patent/MX2016010056A/es unknown
- 2015-02-04 CN CN201580017702.3A patent/CN106458985B/zh not_active Expired - Fee Related
- 2015-02-04 RU RU2016135637A patent/RU2016135637A/ru not_active Application Discontinuation
- 2015-02-04 SG SG11201606367YA patent/SG11201606367YA/en unknown
- 2015-02-04 JP JP2016550611A patent/JP6532474B2/ja not_active Expired - Fee Related
- 2015-02-04 KR KR1020167024669A patent/KR20160118345A/ko not_active Application Discontinuation
- 2015-02-04 EP EP15705447.9A patent/EP3102569A1/en not_active Withdrawn
- 2015-02-04 AU AU2015214366A patent/AU2015214366B2/en not_active Ceased
- 2015-02-04 WO PCT/US2015/014380 patent/WO2015119998A1/en active Application Filing
- 2015-02-04 CA CA2938719A patent/CA2938719A1/en not_active Abandoned
- 2015-02-04 BR BR112016017996A patent/BR112016017996A2/pt not_active Application Discontinuation
- 2015-02-04 US US14/613,579 patent/US9452986B2/en active Active
-
2016
- 2016-07-28 IL IL247014A patent/IL247014A0/en unknown
- 2016-08-17 US US15/239,554 patent/US9969693B2/en active Active
-
2017
- 2017-05-18 HK HK17105028.6A patent/HK1231471A1/zh unknown
-
2018
- 2018-04-13 US US15/952,682 patent/US20180334435A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005014558A1 (en) * | 2003-08-05 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Condensed pyramidine compounds as inhibitors of voltage-gated ion channels |
WO2006124744A1 (en) * | 2005-05-16 | 2006-11-23 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of ion channels |
WO2007003419A1 (en) * | 2005-07-04 | 2007-01-11 | Karo Bio Ab | Heterocyclic compounds as agonists for the thyroid receptor |
WO2007127183A1 (en) | 2006-04-26 | 2007-11-08 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
WO2010137351A1 (en) * | 2009-05-29 | 2010-12-02 | Raqualia Pharma Inc. | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers |
WO2014120815A1 (en) * | 2013-01-31 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Quinoline and quinazoline amides as modulators of sodium channels |
Non-Patent Citations (32)
Title |
---|
"Fundamental Stereochemistry", PURE APPL. CHEM., vol. 45, 1976, pages 13 - 30 |
"Methods in Cell Biology", vol. XIV, 1976, ACADEMIC PRESS, pages: 33 |
BENENG K ET AL., BMC NEUROSCI, vol. 11, 2010, pages 71 |
CUMMINS TR ET AL., EXPERT REV NEUROTHER, vol. 7, 2007, pages 1597 - 1612 |
DIB-HAJJ SD ET AL., ANNU REV NEUROSCI, vol. 33, 2010, pages 325 - 347 |
DIB-HAJJ SD ET AL., BRAIN, vol. 128, 2005, pages 1847 - 1854 |
DIB-HAJJ SD ET AL., NAT REV NEUROSCI., vol. 14, 2013, pages 49 - 62 |
ELIEL, E. L.; WILEN, S. H.: "Stereochemistry of Organic Compounds", 1994, JOHN WILEY & SONS, INC., pages: 119 - 120,1206 |
FABER CG ET AL., ANN NEUROL, vol. 72, 2012, pages 26 - 39 |
FABER CG ET AL., PROC NATL ACAD SCI USA., vol. 109, 2012, pages 19444 - 19449 |
FABER CG ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 109, 2012, pages 19444 - 19449 |
FURNISS; HANNAFORD; SMITH; TATCHELL: "Vogel's Textbook of Practical Organic Chemistry", 1989, LONGMAN SCIENTIFIC & TECHNICAL |
GOLDIN AL ET AL., NEURON, vol. 28, 2000, pages 365 - 368 |
HARGUS NJ ET AL., EXPERT OPIN INVEST DRUGS, vol. 16, 2007, pages 635 - 646 |
HONG S ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, 2004, pages 29341 - 29350 |
LIUM ET AL., PAIN MED, vol. 12, no. 3, 2011, pages S93 - 99 |
MALFAIT, A-M ET AL., NAT. REV. RHEUMATOL., vol. 9, 2013, pages 654 - 664 |
MCGOWAN E ET AL., ANESTH. ANALG., vol. 109, 2009, pages 951 - 958 |
MINETT MS ET AL., NAT COMMUN, vol. 3, 2012, pages 791 |
MOMIN A ET AL., CURR OPIN NEUROBIOL, vol. 18, 2008, pages 383 - 388 |
NASSAR MA ET AL., MOL PAIN, vol. 1, 2005, pages 24 - 31 |
NASSAR MA ET AL., PROC NATL ACAD SCI USA, vol. 101, 2004, pages 12706 - 12711 |
PERSSON AK ET AL., EXP NEUROL., vol. 230, 2011, pages 273 - 279 |
PGM WUTS; TW GREENE: "Greene's book titled Protective Groups in Organic Synthesis", 2006, JOHN WILEY & SONS |
REIMANN F ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 107, 2010, pages 5148 - 5153 |
RUSH AM ET AL., J PHYSIOL, vol. 579, 2007, pages 1 - 14 |
SCHUELERT N ET AL., ARTHRITIS RESEARCH & THERAPY, vol. 14, 2012, pages R5 |
SHIELDS SD ET AL., PAIN, vol. 32, 2012, pages 10819 - 10832 |
STAUNTON CA ET AL., CURRENT PAIN AND HEADACHE REPORTS, vol. 17, 2013, pages 378 |
STRICKLAND IT ET AL., EUROPEAN JOURNAL OF PAIN, vol. 12, 2008, pages 564 - 572 |
WAXMAN SG, BRAIN, vol. 133, 2010, pages 2515 - 2518 |
WAXMAN SG, NATURE, vol. 472, 2011, pages 173 - 174 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10995100B2 (en) | 2014-01-13 | 2021-05-04 | Aurigene Discovery Technologies Limited | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors |
US11691987B2 (en) | 2014-01-13 | 2023-07-04 | Aurigene Discovery Technologies Limited | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors |
JP2017518348A (ja) * | 2014-06-20 | 2017-07-06 | オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited | Irak4阻害剤としての置換インダゾール化合物 |
US10441586B2 (en) | 2015-10-07 | 2019-10-15 | Arizona Board Of Regents On Behalf Of The University Of Arizona | CRMP2 SUMOylation inhibitors and uses thereof |
US11020391B2 (en) | 2015-10-07 | 2021-06-01 | Arizona Board Of Regents On Behalf Of The University Of Arizona | CRMP2 sumoylation inhibitors and uses thereof |
US11419875B2 (en) | 2017-03-31 | 2022-08-23 | Aurigene Discovery Technologies Limited | Compounds and compositions for treating hematological disorders |
US10758518B2 (en) | 2017-10-31 | 2020-09-01 | Curis, Inc. | Compounds and compositions for treating hematological disorders |
WO2020054657A1 (ja) | 2018-09-10 | 2020-03-19 | 科研製薬株式会社 | 新規ヘテロ芳香族アミド誘導体及びそれを含有する医薬 |
KR20210057008A (ko) | 2018-09-10 | 2021-05-20 | 가껭세이야꾸가부시기가이샤 | 신규한 헤테로방향족 아미드 유도체 및 이를 함유하는 약제 |
Also Published As
Publication number | Publication date |
---|---|
RU2016135637A3 (pt-PT) | 2018-08-27 |
US20170226062A9 (en) | 2017-08-10 |
KR20160118345A (ko) | 2016-10-11 |
RU2016135637A (ru) | 2018-03-12 |
IL247014A0 (en) | 2016-09-29 |
MX2016010056A (es) | 2016-11-15 |
AU2015214366A1 (en) | 2016-08-18 |
HK1231471A1 (zh) | 2017-12-22 |
EP3102569A1 (en) | 2016-12-14 |
BR112016017996A2 (pt) | 2017-08-08 |
CN106458985B (zh) | 2019-05-03 |
SG11201606367YA (en) | 2016-09-29 |
CN106458985A (zh) | 2017-02-22 |
AU2015214366B2 (en) | 2019-04-18 |
CA2938719A1 (en) | 2015-08-13 |
US20150218102A1 (en) | 2015-08-06 |
US9969693B2 (en) | 2018-05-15 |
US20180334435A1 (en) | 2018-11-22 |
US9452986B2 (en) | 2016-09-27 |
JP6532474B2 (ja) | 2019-06-19 |
JP2017505327A (ja) | 2017-02-16 |
US20160355482A1 (en) | 2016-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9969693B2 (en) | 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use | |
AU2021200951B2 (en) | Benzolactam compounds as protein kinase inhibitors | |
US20220402915A1 (en) | Bcl-2 inhibitors | |
AU2019200249B2 (en) | Biheteroaryl compounds and uses thereof | |
JP7073359B2 (ja) | ユビキチン特異的プロテアーゼ7の阻害剤としてのピペリジン誘導体 | |
AU2024200566A1 (en) | Pyridazinones as PARP7 inhibitors | |
EP2534151B1 (en) | 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds | |
IL266305A (en) | History [4,2,1] triazolo [5,1-a] pyrimidine as pde2 inhibitors | |
US9777020B2 (en) | Furo-3-carboxamide derivatives and methods of use | |
JP2017503838A (ja) | 6−フェニル−または6−(ピリジン−3−イル)インダゾール誘導体および使用方法 | |
CN114907358A (zh) | 含吡啶多环类衍生物调节剂、其制备方法和应用 | |
US9783527B2 (en) | Indazole ureas and method of use | |
WO2023278402A1 (en) | Smarca degraders and uses thereof | |
WO2023239645A1 (en) | Smarca degraders and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15705447 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 247014 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2938719 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/010056 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2016550611 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015705447 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015705447 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016017996 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2015214366 Country of ref document: AU Date of ref document: 20150204 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016135637 Country of ref document: RU Kind code of ref document: A Ref document number: 20167024669 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112016017996 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160803 |